Insight into Cross-Amyloid Interactions and Morphologies: Molecular Dynamics Simulations of Model Peptide Fragments of Amyloid-β (Aβ16-22) and Islet Amyloid Polypeptide (IAPP20-29)

N. Cramer,¹ G. Kawecki,¹,² K. M. King¹, D. R. Bevan¹,² and A.M. Brown¹-³*

**Keywords:** molecular dynamics simulations, amyloids, amyloid beta, IAPP, amylin, Alzheimer's disease, Type II diabetes

* Corresponding author
  Email:
Abstract

Amyloid-beta (Aβ) and islet amyloid polypeptide (IAPP) are small peptides, classified as amyloids, that have the potential to self-assemble and form cytotoxic species, such as small soluble oligomers and large insoluble fibrils. The formation of Aβ aggregates facilitates the progression of Alzheimer’s disease (AD), while IAPP aggregates induce pancreatic β-cell apoptosis, leading to exacerbation of Type 2 diabetes (T2D). Cross-amyloid interactions between Aβ and IAPP have been described both in vivo and in vitro, implying the role of Aβ or IAPP as modulators of cytotoxic self-aggregation of each peptide, and suggesting that Aβ-IAPP interactions are a potential molecular link between AD and T2D. Using molecular dynamics simulations, “hot spot” regions of the two peptides were studied to understand the formation of hexamers in a heterogenous and homogenous peptide-containing environment. Systems of only Aβ(16-22) peptides formed antiparallel, β-barrel-like structures, while systems of only IAPP(20-29) peptides formed stacked, parallel beta strands and had relatively unstable aggregation structures after 2 μs of simulation time. Systems containing both Aβ and IAPP (1:1 ratio) hexamers showed antiparallel, β-barrel-like structures, with an interdigitated arrangement of Aβ(16-22) and IAPP(20-29). These β-barrel structures have features of cytotoxic amyloid species identified in previous literature. Ultimately, this work seeks to provide atomistic insight into both the mechanism behind cross-amyloid interactions and structural morphologies of these toxic amyloid species.

Statement of Significance

Molecular knowledge, biophysical characterization, structural morphologies, and formation pathways of amyloid oligomers - specifically low-molecular weight, cross-amyloid oligomers - remain preliminary and undefined. Characterizing interactions between homogenous and heterogenous amyloid oligomers is of great interest given that certain oligomer morphologies contribute to cytotoxicity, eventually resulting in comorbid diseases such as Alzheimer’s disease (AD) and Type 2 Diabetes Mellitus.
(T2DM). Utilizing model systems (e.g., fragments of full-length peptides) and molecular dynamics (MD) simulations to probe the biophysical underpinnings of cross-amyloid oligomer structures is the first step in understanding the dynamics, stability, and potential modes of cytotoxicity of these species, providing important insights into targetable biomolecular structures.
Introduction

The accumulation of amyloidogenic peptides into morphologically variable aggregates and highly-ordered plaques are hallmarks of amyloid diseases\(^1\)-\(^3\). Amyloid diseases constitute a variety of degenerative disorders, including Alzheimer’s Disease (AD) and Type 2 Diabetes (T2D). In 2020, T2D and AD affected an estimated 6 million\(^4\) and 30 million\(^5\) Americans, and are the sixth and seventh leading causes of death in the US, respectively\(^6\). AD, the most prevalent form of dementia, is characterized by neuronal cell degradation and death\(^7\). T2D is characterized by insulin insensitivity and impaired pancreatic \(\beta\)-cell function, and is exacerbated by poor diet, lack of exercise, and a host of other genetic and environmental factors\(^8,9\). While both AD and T2D are characterized as individual pathologies, these diseases are highly comorbid. Evidence implicates AD and T2D in mutual pathogenic pathways via overlapping molecular mechanisms\(^10\)-\(^12\), and each increases the risk for the other\(^13\)-\(^15\). Furthermore, AD pathology alters insulin signaling pathways in the brain\(^16\), suggesting AD is implicated in Type III Diabetes\(^17\).

AD and T2D pathologies are associated with the amyloidogenic peptides amyloid-\(\beta\) (A\(\beta\))\(^18\)-\(^21\) and the islet amyloid polypeptide (IAPP or amylin)\(^22\)-\(^25\), respectively. Both A\(\beta\) and IAPP are capable of self-assembling\(^26\)-\(^29\) into cytotoxic species of variable morphologies, specifically fibrils\(^30\)-\(^33\) and oligomers\(^20, 34, 35\). These oligomers, particularly low-molecular weight oligomers, have been identified as key contributors to the onset of each disease and are capable of cross-amyloid interactions\(^36\)-\(^38\). Elucidating the mechanisms by which these amyloids aggregate and their resultant structural morphologies can provide insight into the pathogenic events of each disease, allow
assessment of the extent of their comorbidity at the molecular level, and provide insight into therapeutic design to disrupt cross-amyloid formation.

Fibrillar amyloid morphologies generally exhibit a cross-β structure, composed of repeating β-strand monomers arranged in a steric zipper\textsuperscript{39, 40}. Oligomers formed on-pathway to fibrillar aggregate formation are thought to be the primary cytotoxic species in amyloid diseases\textsuperscript{41, 42}. These have been found to non-specifically destabilize cellular membranes and cause ionic leakage and impaired Ca\textsuperscript{2+} regulation by the formation of β-barrel structures\textsuperscript{43-45}. Amyloid β-barrels are thought to be composed of a low number of peptide subunits, each assuming a U-shaped ‘β-strand-turn-β-strand’ motif common to most amyloids, and stacked annularly, parallel, and usually in-register to form the barrel.\textsuperscript{46, 47} Cytotoxic β-barrels comprised of out-of-register subunits have also been identified\textsuperscript{48}.

Common structural features of amyloid oligomers and their mechanisms of membrane perturbation have yet to be described at an atomistic level, likely due to their transient nature and widely varying structural morphologies. Molecular dynamics (MD) simulations are ideal for investigating oligomerization events, allowing us to characterize their formation, structure, and stability. To date, MD simulations have been utilized to describe oligomerization of full-length Aβ\textsuperscript{49, 50} and IAPP\textsuperscript{51, 52}, and to determine which portions of their sequences are necessary and sufficient for inducing aggregation and providing stability. In particular, the core hydrophobic regions, composed of residues 16-22 of Aβ (KLVFFAE) and residues 20-29 of IAPP (SNNFGAILSS), have been shown to exhibit similar aggregation potential as full-length peptides\textsuperscript{53, 54}, and thus are of primary interest as model peptide fragments for studying aggregation.
Previous work characterizing fragments of Aβ and IAPP has provided foundational evidence for modeling these particular fragments. Residues 20-29 of IAPP (IAPP(20-29)) form the spine of IAPP fibrils under physiological conditions\textsuperscript{40}, indicating the ability of this fragment to participate in β-strand formation and its importance for aggregate stability. Furthermore, the primary sequence of this fragment is poorly conserved in IAPP analogues from other species that do not exhibit amyloidogenic properties,\textsuperscript{55} indicating that this fragment is influential in the human IAPP aggregation pathway. Likewise, residues 16-22 of Aβ (Aβ(16-22)) include the central hydrophobic core of full-length Aβ, which is capable of forming aggregates itself\textsuperscript{56} and is essential for the aggregation of the full-length peptide.\textsuperscript{57} Furthermore, residues 16-22 of Aβ exist in a natively helical state; a conformational transition of this region to a coiled state capable of integrating into β-strands is considered a major rate-limiting step in Aβ aggregation\textsuperscript{36}, and interactions between IAPP and this region of Aβ may facilitate this conformational change and subsequently promote co-aggregation.\textsuperscript{36,58} Full-length Aβ and IAPP share approximately 25% sequence identity and 50% sequence similarity, with the greatest conservation occurring within these “hot spot” regions\textsuperscript{59}; as such, these fragments likely play a central role in cross-amyloid aggregation.

Here, we utilized MD simulations to observe Aβ(16-22) and IAPP(20-29) hexamer formation, using both homogeneous and mixed systems, to provide detailed insight into the structural transitions and architecture of these amyloid fragments. This work describes the underlying structural organization and inter-peptide interactions that these model peptides sample in route to an organized, β-strand rich oligomer structure.
Methods

The MD simulation package GROMACS (version 2018.1) was used to simulate hexamer formation for all systems using the GROMOS96 53a6 force field. A total of 12 systems (4 replicates of each system type: Aβ(16-22) only, IAPP(20-29) only, or Aβ(16-22)+IAPP(20-29) in a 1:1 ratio) were first created by the random placement of 6 copies of peptide fragments in a 13×13×13 nm cubic box. A schematic representation of system design is shown in Figure 1. Peptide fragments of Aβ(16-22) were extracted from full-length Aβ(1-42) (PDB: 1IYT), and fragments of IAPP(20-29) from full-length IAPP(1-37) (PDB: 2L86). All peptide fragments were capped by acetylation at the N-terminus and amidation at the C-terminus. A minimum inter-peptide starting distance of >1.4 nm between the closest two atoms of each peptide fragment was utilized to be beyond the nonbonded cutoff for van der Waals interactions at the onset of the simulation. Systems were then solvated with simple point charge (SPC) water and ionized with 0.150 mM NaCl and counter-ions to preserve a net neutral system.

The steepest-descent method was employed for energy minimization, after which all systems were subjected to an equilibration by a canonical (NVT) ensemble to maintain temperature of the system at 310K using the Berendsen weak coupling method, for 100 ps. Each replicate system utilized different, randomly selected starting velocities assigned at the onset of NVT. An isothermal-isobaric (NPT) ensemble was then employed for a subsequent 100 ps to equilibrate the systems to a pressure of 1 bar using the V-rescale modified Berendsen temperature coupling method and Parrinello-Rahman barostat. Positional restraints were imposed on peptide atoms during equilibration and released afterward. Bond lengths were constrained using Parallel Linear Constraint
Solver (P-LINCS)\textsuperscript{68} with an integration time step of 2 fs. The smooth Particle-Mesh Ewald method (PME)\textsuperscript{69, 70} was used for calculating long-range electrostatics using cubic interpolation. A Fourier grid spacing of 0.16 nm, three-dimensional periodic boundary conditions, and a real-space coulomb cutoff of 1.4 nm were also utilized. Input parameter files, coordinate files, and scripts utilized in this study are located on our Open Science Framework page (https://osf.io/82n73/).

MD production was performed for 2 µs for all replicates in each molecular system for a total simulation time of 24 µs. Root-mean-square-deviation (RMSD) analysis was used to determine simulation convergence for each system; subsequent, aggregate analysis was then conducted over the last 500 ns of each simulation to ensure the characterization of stable hexamers and provide adequate sampling time (6 µs) (Figures S1-S3). RMSD-based clustering of backbone atoms was conducted based on an RMSD cutoff of 0.3 nm, originally based on the work of Darua et al.\textsuperscript{71} but expanded to amyloid oligomers in the work of Brown et al.\textsuperscript{72}, to identify dominant hexamer morphologies for every 100 ns block and for the last 500 ns of each replicate system. Clustered structures were then visualized and rendered in PyMOL (version 2.2.0).\textsuperscript{73} Secondary structure was assessed using the Dictionary of Secondary Structure Program (DSSP).\textsuperscript{74} Hexameric shape was assessed by calculating eccentricity ($e$) from the three moments of inertia ($I_1$, $I_2$, and $I_3$) and semiaxes $a$, $b$, and $c$, as previously described.\textsuperscript{72, 75, 76} Other analysis, including hydrogen bonding, radius of gyration, and residue-residue contacts were performed using GROMACS analysis tools and in-house scripts. All averages presented were calculated over four replicates for each simulation system and are presented with
the corresponding standard deviation. A two-tailed t-test was used for statistical analysis, with statistical significance determined as $p < 0.05$.

**Figure 1. Schematic overview of simulation progression and analysis.** Four replicate trajectories per hexamer type were simulated for 2 µs each, providing a cumulative sampling time of 8 µs per hexamer type ($A\beta_{(16-22)}$, $IAPP_{(20-29)}$, and $A\beta_{(16-22)} + IAPP_{(20-29)}$) (Left). Primary sequence of $A\beta_{(16-22)}$ and $IAPP_{(20-29)}$ fragments simulated, highlighted in blue. Overview of analyses performed on final hexamer structures obtained in the last 500 ns of simulation (Right).
Results and Discussion

Detailed descriptions of amyloid morphologies and stepwise aggregation events are necessary for understanding and preventing the progression of amyloid diseases like AD and T2D. However, the stochastic nature of these events makes atomistic characterization of aggregate structure particularly difficult. Thus, MD simulations are a valuable tool for providing foundational insight into these mechanisms and identifying potentially targetable structures or co-interaction capabilities. Here, we utilized united-atom MD simulations to model the aggregation of $\text{A}\beta_{(16-22)}$ and $\text{IAPP}_{(20-29)}$ in both homogenous and heterogenous (mixed) systems. The selected fragments constitute the regions driving oligomerization of $\text{A}\beta$ and $\text{IAPP}$, and thus serve as a computationally efficient model system that can be extrapolated to the full-length peptides. Through this work, we provide detailed morphological descriptions of co-aggregated $\text{A}\beta_{(16-22)}$ and $\text{IAPP}_{(20-29)}$ hexamers and their comparison to homogenous systems, as well as the use of these short peptide fragments for simulating full-length amyloid aggregation events and morphologies.
Identifying morphologies of homogenous and heterogenous systems of Aβ<sub>(16-22)</sub> and IAPP<sub>(20-29)</sub>

**Figure 2.** Secondary structure over time and representative structures from RMSD clustering for Aβ<sub>(16-22)</sub>, (B) IAPP<sub>(20-29)</sub>, and (C) Aβ<sub>(16-22)</sub> + IAPP<sub>(20-29)</sub>. The percentage of residues exhibiting each secondary structure type was averaged across four replicate trajectories for each system type, and block averaged every 1 ns are shown. Cluster structures from replicates with the highest cluster percentage and similarity to average secondary structure of all replicates represent morphologies of the last 500 ns of simulation. (A) Aβ<sub>(16-22)</sub> is colored gray, (B) IAPP<sub>(20-29)</sub> is colored gray (C) IAPP<sub>(20-29)</sub> is colored blue, and Aβ<sub>(16-22)</sub> is colored...
Adoption of β-strand content is indicative of amyloid aggregation pathways. As such, monitoring the progression of secondary structure allows us to identify canonical on-pathway aggregation. To properly model secondary structure of Aβ(16-22) and IAPP(20-29), force field selection is critical and must be taken into account in system construction and in analysis outcomes. The GROMOS96 53a6 forcefield has been shown to model β-strand formation of Aβ in agreement with experimental data, with other force fields tending to over-stabilize α-helices. For the purposes of this work and based on our previous force field comparison study, the GROMOS96 53a6 was chosen for modelling Aβ and IAPP fragments. A recent review highlights that there are three major problems to consider in simulating amyloid aggregation, including insufficiently accurate force fields, protein concentration, and time-scale limits. More work is necessary to further refine force fields for both the field of IDPs, for model systems, and for aggregation processes, with this work contributing how one force field models similarities and differences between model systems of homogenous and mixed amyloid formation. This work focuses on homogenous and mixed amyloid structure formation on that facet and does not seek to be a comparison between force fields. Furthermore, recent work from discrete MD (DMD) simulations of full-length Aβ42 hexamer formation indicate a β-barrel formation in line with the results discussed below, as well as in vivo experimental validation, that highlighted the formation the β-barrel oligomers of Aβ42. To describe aggregate structure with respect to secondary structure content, secondary structure over time for each system was assigned using the DSSP algorithm. Aβ control hexamers showed a rapid timewise transition from 100% random coil at MD onset to 51% ± 4 β-strand structure over the last 500 ns of simulation (Figure 2A, Table 1). Likewise, IAPP control hexamers showed a similarly rapid progression from predominantly random coil at the onset of MD, stabilizing at 48% ± 8 β-strand structures in the last 500 ns of simulation (Figure 2B, Table 1). These data match previous analyses of secondary structure content of amyloid oligomers, which adopt β-strand structure on-pathway to aggregation. Fragments adopting experimentally determined secondary structure content supports the use of GROMOS 53a6 for modelling these fragments.
Mixed Aβ+IAPP hexamers exhibited the same rapid progression from predominantly coil to greater β-strand content, reaching 42% ± 8 β-strand content in the last 500 ns, though the percentage is lower than observed for Aβ_{16-22} and IAPP_{20-29} control systems (Figure 2C, Table 1). This apparent decrease in β-strand content may be attributed to differing length of the two fragment types (7 residues for Aβ_{16-22} vs 10 residues for IAPP_{20-29}). Indeed, structures from RMSD clustering show the terminal ends of the longer IAPP_{20-29} fragment adopting random coil secondary structure (Figure S4).

Table 1. Average post-convergence secondary structure percentages and standard deviations by system. Values were obtained by sampling the last 0.5 µs of four replicate trajectories per system for a total sampling time of 2 µs per hexamer type.

| System       | Coil  | β-Strand | α-Helix |
|--------------|-------|----------|---------|
| Aβ Control   | 49 ± 4| 51 ± 4   | 0 ± 0   |
| IAPP Control | 52 ± 8| 48 ± 8   | 0 ± 0   |
| Aβ+IAPP      | 58 ± 8| 42 ± 8   | 0 ± 0   |

Given the polymorphic nature of amyloid oligomers, the most targetable motifs are likely found in tandem with the most stable or common morphologies. Thus, to characterize dominant morphologies of each hexamer type, clustering analysis was performed over the last 500 ns of simulation (Figure 2, Figures S5-S7) and over 100 ns time periods over the 2 µs simulation (Figures S8-S19). Dominant morphologies for Aβ_{16-22} replicates over the last 500 ns of simulation included β-barrel-like structures and stacked β-strand pairs consisting of trimer/trimer and tetramer/dimer configurations (Figure 2A, Figures S5, S8-S11). β-strands tend to be antiparallel, although some parallel strands are observed. These structures are in agreement with previous literature; Aβ oligomers favor a variety of comparable structures based on the lack of a single local minima in a free energy landscape, adopting several localized energy basins representing stacked beta strands\(^{84, 85}\) or barrel-like structures\(^{86, 87}\).

IAPP_{20-29} oligomers instead formed either shorter-length β-strands interspersed by random coil, or a single, tightly curved strands reminiscent of open-conformation β-barrels (Figure 2B, Figures S6, S12-S15). Both parallel and anti-parallel β-strands are observed, although parallel is dominant. Computational work performed by Sun et al.\(^{50}\)
describes a progression of events during IAPP aggregation that may provide a mechanical link between the structures seen here, in which oligomerized peptides initially form short β-strands flanked by random coil, which then elongate and form a single β-strand capable of curling and adopting a barrel-like structure. The apparent frequency of the structures obtained for Aβ\textsubscript{(16-22)} and IAPP\textsubscript{(20-29)} in the literature suggest that these structures are representative of on-pathway oligomers.

Mixed hexamers composed of Aβ\textsubscript{(16-22)} and IAPP\textsubscript{(20-29)} generally exhibited barrel-like morphologies, with all four systems showing noticeable pore-like architecture (Figure 2C, Figures S7, S16-S19). Typically, mixed Aβ\textsubscript{(16-22)} and IAPP\textsubscript{(20-29)} structures displayed an interdigitated arrangement of Aβ\textsubscript{(16-22)} and IAPP\textsubscript{(20-29)} peptides, usually arranged in parallel β-strands. Similar β-barrel structures have been observed in other computational work studying Aβ-IAPP fragment co-aggregation\textsuperscript{88}. Furthermore, hydrogen exchange mass spectrometry\textsuperscript{89} and NMR\textsuperscript{86} experiments with full-length Aβ reveal that β-barrel oligomers are formed on pathway to aggregation, suggesting that the fragment model system is representative of full-length co-aggregation behavior. Interestingly, the β-barrel oligomer formed by the amyloidogenic αB crystallin peptide, named cylindrin, has been found to exhibit cytotoxicity\textsuperscript{90}. Thus, it is possible that co-aggregated IAPP and Aβ exert cytotoxicity via β-barrel formation and when in mixed amyloid systems, have a higher propensity for β-barrel formation and more ordered structures than when in homogenous systems.
Determining aggregate structures for basic mechanistic insight into disease progression is dependent on structural stability. As such, we sought to determine the relative stability of each hexamer. To estimate structural stability, cluster structure percentages, solvent-accessible surface area (SASA), and free energy calculations were examined. Clustering percentages indicate the percentage of frames within 0.3 nm of a given structure; as such, higher clustering percentages signify more conformational stability. On average, Aβ\textsubscript{(16-22)} hexamers were determined to be more stable and unchanging morphologically than both IAPP\textsubscript{(20-29)} and mixed Aβ\textsubscript{(16-22)} + IAPP\textsubscript{(20-29)} hexamers as indicated by clustering percentages calculated from the last 500 ns of each simulation (Table 2). Interestingly, Aβ hexamers exhibited the most favorable total free energy despite having a larger hydrophobic solvent-accessible surface area relative to IAPP and mixed systems (Table 2). This increased stability is likely due to a combination of aromatic-hydrophobic and charged inter-peptide interactions. Aromatic interactions were observed to be high-probability interactions in residue network maps (Figure 3), and cluster structures revealed that solvent-exposed phenylalanine residues exhibited
ordered stacking interactions in replicates with less structural polymorphism (See Figure S20). Furthermore, the charged side chains on the terminal residues of Aβ(16-22) likely contribute to structural stability; the average minimum distance between Aβ terminal residues (0.93 ± 0.04 nm) are significantly different from distances between terminal residues IAPP (1.16 ± 0.03 nm) or mixed systems (1.70 ± 0.05 nm), which are polar/polar and charged/polar, respectively (Table 2). This indicates that contacts between Aβ terminal residues are closer; potential salt bridges were observed in replicates 1, 2, and 3 (Figure S21). These interactions between charged terminal residues may account for the increased stability seen in Aβ systems.

IAPP(20-29) hexamers were the most polymorphic of any of the systems, exhibiting the most numerous cluster structures sampled over the last 500 ns of simulation (Table 2). Furthermore, the free energy of IAPP systems was on average the most favorable with the lowest free energy calculation of the final formed morphologies, with the lowest amount of hydrophobic SASA over the last 500 ns of simulation (Table 2). IAPP, like Aβ, benefits from strong interactions between hydrophobic residues (Figure 3). We predict that IAPP systems were more energetically favorable given the decrease in order and barrel formation observed as compared to Aβ only systems. Interestingly, IAPP is modestly more compact than the Aβ and mixed systems as assessed by radius of gyration, suggesting that hydrophobic packing is strongest in IAPP systems (Table 2). The reduced stability in IAPP systems is likely due to weaker interactions from flanking polar residues relative to Aβ; average minimum distance between the polar termini was longer than distance between charged terminal residues in Aβ (Table 2). The polar termini are thus more flexible, and likely contribute to the structural polymorphism.

Mixed Aβ(16-22) + IAPP(20-29) hexamers mediate characteristics of homogenous Aβ(16-22) and IAPP(20-29) systems in terms of stability based on clustering, free energy, SASA and compactness (Table 2). Like their substituents, mixed systems likely derive stability from strong hydrophobic interactions between the cores of each peptide, where tight hydrophobic packing is observed in network maps (Figure 3). In particular, Aβ Phe residues have high probability of interaction with other Aβ Phe and IAPP Leu residues, packing in the core of the barrel (Figure S22). However, much like IAPP(20-29), the mixed systems exhibited less frequent contacts between flanking polar/charged residues than
did Aβ or IAPP (Table S2). This can be attributed to the differing length between the two peptides, often leaving the N-terminal region of IAPP disordered in the simulations. There was a significant increase in free energy favorability of the mixed Aβ\textsubscript{(16-22)} + IAPP\textsubscript{(20-29)} compared to homogenous systems of Aβ. While the overall morphology of Aβ\textsubscript{(16-22)} + IAPP\textsubscript{(20-29)} systems mimicked Aβ-only systems, and the structural morphology of a β-barrel was more consistent and defined, the energetic favorability for a more ordered structure was observed. This indicated that the presence of both peptides in a mixed system contributed to a more favorable total free energy and ordered structure than individually, which highlights the potentiality of exacerbation of oligomer toxicity in co-amyloid structures.

Table 2. Dominant cluster percentage, solvent accessible surface area (SASA) radius of gyration, free energy averages, and average distance between polar/charged terminal residues. Values were obtained by sampling the last 0.5 µs of four replicate trajectories per system for a total sampling time of 2 µs per hexamer type.
Structural implications related to cytotoxicity of cross-amyloid structures

![Diagram showing internal water molecules and water molecules within 3 Å of solvent-exposed residues](image)

**Figure 4.** Internal water molecules and water molecules within 3 Å of solvent-exposed residues (surface shell). Each morphology represents the central structure of the dominant cluster obtained from the last 0.5 µs of each system. In the left-most columns, IAPP\(_{(20-29)}\) fragments are shown in blue, while Aβ\(_{(16-22)}\) fragments are shown in gray. In the rightmost columns, peptides are shown as a surface, and colored by hydrophobicity (charged blue, polar purple, hydrophobic red).

Combating amyloid diseases like AD and T2D also requires translating these differences in oligomeric structure and stability to relative toxicity. Out-of-register β-strand alignment, leaving staggered hydrogen bonds, has been implicated in the formation of toxic, cylindrin-like amyloids\(^9\). Out-of-register β-strands were observed in mixed Aβ\(_{(16-22)}\) + IAPP\(_{(20-29)}\) replicates. We calculated the average number of hydrogen bonds between residues and water for each system to determine if out-of-register hydrogen bonds are of higher frequency in heterogeneous systems. Hydrogen bonding with water was increased.
in mixed systems, particularly with respect to N-terminal IAPP(20-29) residues Asn21 and Asn22 (Figure S23). If hydrophobic core contacts are preserved in full-length cross-aggregates, out-of-register hydrogen bonds could potentially be present on the N-terminal end of IAPP. This supports the formation of β-barrels for full length cross-aggregates and may provide insight into their toxicity. Additionally, Aβ Glu22 residues were more likely to have an increase in number of hydrogen bonds with water, in both the mixed and homogenous system.

The formation of several distinct pore-like amyloid oligomers have been reported in the literature. It is hypothesized that these structures may confer toxicity by permeabilizing the membrane to ions, leading to cellular dysfunction. While the β-barrel structures observed appear pore-like in shape, the internal cavity of the barrel is generally packed with hydrophobic side chains. As such, barrel-like structures are accordingly unlikely to accommodate passage of significant quantities of water, corroborated by water shell analysis (Figure 4, Figures S24-S26). Similar hydrophobic packing has been observed in other studies examining the formation of pore-like Aβ structures.90 In general, more apparent barrel-like structures appear to accommodate notably less water in the internal cavity due to increased hydrophobic packing, and therefore have less internal surface area for water contact. However, it is worth mentioning that permeability to solvent and ions may be dependent on oligomer size; Aβ 20-mers appear to have characteristics of ion channels.92 Furthermore, disordered oligomers with increased hydrophobic SASA have been identified as cytotoxic,86,87 suggesting that water permeability may be a factor in cytotoxicity.

Conclusions

This work indicates that mixed systems containing both Aβ(16-22) and IAPP(20-29) form β-barrel oligomers, which are potentially cytotoxic and have different structure morphologies and stability when compared to homogenous Aβ(16-22) or IAPP(20-29) hexamers. This difference in homogenous versus mixed amyloid systems is supported by both the clustering analysis and eccentricity analysis, as well as average termini distances. Mixed systems mediate characteristics of both Aβ(16-22) and IAPP(20-29), with the
presence of Aβ likely organizing and influencing β-strand content and morphology over IAPP. Mixed systems of Aβ\textsubscript{(16-22)} and IAPP\textsubscript{(20-29)} consistently formed more organized, interdigitated β-barrel shaped morphologies than homogenous systems. This work highlights the utilization of short, model fragments to simulate the similarities and differences between homogenous and heterogenous amyloid structures. Future work includes molecular dynamics simulations with full length Aβ and IAPP mixed systems to see co-amyloid behavior is comparable to the results obtained from using fragments as model systems, as well as the impact of these morphologies on membrane perturbation as a metric to assess cytotoxicity.

Author Contributions
N.C, D.R.B. and A.M.B. designed research protocol. N.C, G.K., and A.M.B. performed simulations. N.C., G.K, K.M.K, and A.M.B analyzed data. N.C., G.K, D.R.B, and A.M.B. wrote the paper.

Acknowledgments
The authors thank Advanced Research Computing at Virginia Tech for high performance computing resources.

References

[1] Araki, K., Yagi, N., Aoyama, K., Choong, C. J., Hayakawa, H., Fujimura, H., Nagai, Y., Goto, Y., and Mochizuki, H. (2019) Parkinson's disease is a type of amyloidosis featuring accumulation of amyloid fibrils of α-synuclein, Proceedings of the National Academy of Sciences of the United States of America 116, 17963-17969.
[2] Glabe, C. G. (2008) Structural classification of toxic amyloid oligomers, pp 29639-29643, American Society for Biochemistry and Molecular Biology.
[3] Kollmer, M., Close, W., Funk, L., Rasmussen, J., Bsoul, A., Schierhorn, A., Schmidt, M., Sigurdson, C. J., Jucker, M., and Fändrich, M. (2019) Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer’s brain tissue, Nature Communications 10, 1-8.
[4] Association, A. s. (2020) 2020 Alzheimer's Disease Facts and Figures.
[5] Prevention, C. f. D. C. a. (2020) National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States.
[6] Prevention, C. f. D. C. a. (2017) National Vital Statistics Reports.
[7] Association, A. s. D. (2020) Alzheimer’s Disease Facts and Figures.
[8] Cersosimo, E., Triplitt, C., Mandarino, L. J., and DeFronzo, R. A. (2015) Pathogenesis of Type 2 Diabetes Mellitus ncbi, MDText.com, Inc.
[9] Talchai, C., Lin, H. V., Kitamura, T., and Accili, D. (2009) Genetic and biochemical pathways of β-cell failure in type 2 diabetes, *Diabetes, Obesity and Metabolism* 11, 38-45.

[10] Kawahara, M., Kuroda, Y., Arispe, N., and Rojas, E. (2000) Alzheimer's β-amyloid, human islet amylin, and priori protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line, *Journal of Biological Chemistry* 275, 14077-14083.

[11] Lim, Y.-A., Ittner, L. M., Lim, Y. L., and Götz, J. (2008) Human but not rat amylin shares neurotoxic properties with Aβ42 in long-term hippocampal and cortical cultures, *FEBS Letters* 582, 2188-2194.

[12] Luca, S., Yau, W. M., Leapman, R., and Tycko, R. (2007) Peptide conformation and supramolecular organization in amylin fibrils: Constraints from solid-state NMR, *Biochemistry* 46, 13505-13522.

[13] Haroon, N. N., Austin, P. C., Shah, B. R., Wu, J., Gill, S. S., and Booth, G. L. (2015) Risk of dementia in seniors with newly diagnosed diabetes: A Population-Based study, *Diabetes Care* 38, 1868-1875.

[14] Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Kanba, S., and Kiyohara, Y. (2011) Glucose tolerance status and risk of dementia in the community: The Hisayama Study, *Neurology* 77, 1126-1134.

[15] Rawlings, A. M., Sharrett, A. R., Schneider, A. L. C., Coresh, J., Albert, M., Couper, D., Griswold, M., Gottesman, R. F., Wagenknecht, L. E., Windham, B. G., and Selvin, E. (2014) Diabetes in midlife and cognitive change over 20 years: A cohort study, *Annals of Internal Medicine* 161, 785-793.

[16] Gabbouj, S., Ryhänen, S., Marttinen, M., Wittrahm, R., Takalo, M., Kemppainen, S., Martiskainen, H., Tanila, H., Haapasalo, A., Hiltunen, M., and Natunen, T. (2019) Altered Insulin Signaling in Alzheimer's Disease Brain - Special Emphasis on PI3K-Akt Pathway, *Front Neurosci* 13, 629-629.

[17] Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., and Giau, V. V. (2020) Type 3 Diabetes and Its Role Implications in Alzheimer's Disease, *International journal of molecular sciences* 21, 3165.

[18] Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., and Yednock, T. (2000) Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease, *Nature Medicine* 6, 916-919.

[19] Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., and LaFerla, F. M. (2005) Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice, *Neuron* 45, 675-688.

[20] Lee, J. C., Kim, S. J., Hong, S., and Kim, Y. S. (2019) Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers, pp 1-10, Nature Publishing Group.

[21] Zetterberg, H., and Schott, J. M. (2019) Biomarkers for Alzheimer's disease beyond amyloid and tau, pp 201-203, Nature Publishing Group.

[22] Chaari, A., and Ladjimi, M. (2019) Human islet amyloid polypeptide (hIAPP) aggregation in type 2 diabetes: Correlation between intrinsic physicochemical properties of hIAPP aggregates and their cytotoxicity, *International Journal of Biological Macromolecules* 136, 57-65.

[23] Jurgens, C. A., Toukatly, M. N., Fligner, C. L., Udayasankar, J., Subramanian, S. L., Zraika, S., Aston-Mourney, K., Carr, D. B., Westermark, P., Westermark, G. T., Kahn, S. E., and Hull, R. L. (2011) β-Cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition, *American Journal of Pathology* 178, 2632-2640.
[24] Kahn, S. E., Andrikopoulos, S., and Verchere, C. B. (1999) Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes, pp 241-253, American Diabetes Association Inc.

[25] Pilkington, E. H., Gurzov, E. N., Kakinen, A., Litwak, S. A., Stanley, W. J., Davis, T. P., and Ke, P. C. (2016) Pancreatic β-Cell Membrane Fluidity and Toxicity Induced by Human Islet Amyloid Polypeptide Species, *Scientific Reports* 6, 1-10.

[26] Guo, A. Z., Flitt, A. M., and De Pablo, J. J. (2018) Early-stage human islet amyloid polypeptide aggregation: Mechanisms behind dimer formation, *Journal of Chemical Physics* 149, 025101-025101.

[27] Kumar, S., and Walter, J. (2011) Phosphorylation of amyloid beta (Aβ) peptides - A trigger for formation of toxic aggregates in Alzheimer's disease, *Aging* 3, 803-812.

[28] Padrick, S. B., and Miranker, A. D. (2002) Islet amyloid: Phase partitioning and secondary nucleation are central to the mechanism of fibrillogenesis, *Biochemistry* 41, 4694-4703.

[29] Snyder, S. W., Ladorr, U. S., Wade, W. S., Wang, G. T., Barrett, L. W., Matayoshi, E. D., Huffaker, H. J., Krafft, G. A., and Holzman, T. F. (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths, *Biophysical Journal* 67, 1216-1228.

[30] Goldsberry, C. S., Cooper, G. J. S., Goldie, K. N., Müller, S. A., Saafi, E. L., Gruijters, W. T. M., Misur, M. P., Engel, A., Aebl, U., and Kistler, J. (1997) Polymorphic Fibrillar Assembly of Human Amylin, *Journal of Structural Biology* 119, 17-27.

[31] Makin, O. S., Atkins, E., Sikorski, P., Johansson, J., and Serpell, L. C. (2005) Molecular basis for amyloid fibril formation and stability, *Proceedings of the National Academy of Sciences of the United States of America* 102, 315-320.

[32] Pilkington, E. H., Gustafsson, O. J. R., Xing, Y., Hernandez-Fernaud, J., Zamproni, C., Kakinen, A., Faridi, A., Ding, F., Wilson, P., Ke, P. C., and Davis, T. P. (2018) Profiling the Serum Protein Corona of Fibrillar Human Islet Amyloid Polypeptide, *ACS Nano* 12, 6066-6078.

[33] Rusitzka, K. A. K., Stephenson, L. T., Szczepaniak, A., Gremer, L., Raabe, D., Willbold, D., and Gault, B. (2018) A near atomic-scale view at the composition of amyloid-beta fibrils by atom probe tomography, *Scientific Reports* 8, 1-10.

[34] Breydo, L., Kurouski, D., Rasool, S., Milton, S., Wu, J. W., Uversky, V. N., Lednev, I. K., and Glabe, C. G. (2016) Structural differences between amyloid beta oligomers, *Biochemical and Biophysical Research Communications* 477, 700-705.

[35] Breydo, L., and Uversky, V. N. (2015) Structural, morphological, and functional diversity of amyloid oligomers, pp 2640-2648, Elsevier B.V.

[36] Ge, X., Yang, Y., Sun, Y., Cao, W., and Ding, F. (2018) Islet Amyloid Polypeptide Promotes Amyloid-Beta Aggregation by Binding-Induced Helix-Unfolding of the Amyloidogenic Core, *ACS chemical neuroscience* 9, 967-975.

[37] Luo, J., Wärmländer, S. K. T. S., Gräslund, A., and Abrahams, J. P. (2016) Cross-interactions between the Alzheimer disease amyloid-β peptide and other amyloid proteins: A further aspect of the amyloid cascade hypothesis, pp 16485-16493, American Society for Biochemistry and Molecular Biology Inc.

[38] Valera, E., Spencer, B., and Masliah, E. (2016) Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders, pp 179-189, Springer New York LLC.

[39] Park, J., Kahng, B., and Hwang, W. (2009) Thermodynamic selection of steric zipper patterns in the amyloid cross-β spine, *PLoS Computational Biology* 5.

[40] Sawaya, M. R., Sambashivan, S., Nelson, R., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wittius, J. J. W., McFarlane, H. T., Madsen, A., Riekel, C., and Eisenberg, D. (2007) Atomic structures of amyloid cross-β spines reveal varied steric zippers, *Nature* 447, 453-457.
[41] Cline, E. N., Bicca, M. A., Viola, K. L., and Klein, W. L. (2018) The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade, *J Alzheimers Dis* 64, S567-S610.

[42] Haataja, L., Gurlo, T., Huang, C. J., and Butler, P. C. (2008) Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis, *Endocrine Reviews* 29, 303-316.

[43] Berridge, M. J. (2010) Calcium hypothesis of Alzheimer’s disease, *Plügers Archiv - European Journal of Physiology* 459, 441-449.

[44] Di Scala, C., Yahi, N., Boutemeur, S., Flores, A., Rodríguez, L., Chahinian, H., and Fantini, J. (2016) Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein, *Scientific Reports* 6, 28781-28781.

[45] Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabel, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis, *Science* 300, 486-489.

[46] Jang, H., Arce, F. T., Ramachandran, S., Capone, R., Azimova, R., Kagan, B. L., Nussinov, R., and Lal, R. (2010) Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimer’s Disease and Down syndrome, *Proceedings of the National Academy of Sciences of the United States of America* 107, 6538-6543.

[47] Jang, H., Zheng, J., and Nussinov, R. (2007) Models of β-amyloid ion channels in the membrane suggest that channel formation in the bilayer is a dynamic process, *Biophysical Journal* 93, 1943-1949.

[48] Liu, C., Zhao, M., Jiang, L., Cheng, P.-N., Park, J., Sawaya, M. R., Pensalfini, A., Gou, D., Berk, A. J., Glabe, C. G., Nowick, J., and Eisenberg, D. (2012) Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates, *Proceedings of the National Academy of Sciences* 109, 20913-20918.

[49] Lal, R., Lin, H., and Quist, A. P. (2007) Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm, *Biochimica et Biophysica Acta (BBA) - Biomembranes* 1768, 1966-1975.

[50] Sun, Y., Ge, X., Xing, Y., Wang, B., and Ding, F. (2018) β-barrel Oligomers as Common Intermediates of Peptides Self-Assembling into Cross-β Aggregates, *Scientific Reports* 8, 10353-10353.

[51] Baram, M., Atsmon-Raz, Y., Ma, B., Nussinov, R., and Miller, Y. (2016) Amylin-Αβ oligomers at atomic resolution using molecular dynamics simulations: A link between Type 2 diabetes and Alzheimer’s disease, *Physical Chemistry Chemical Physics* 18, 2330-2338.

[52] Caillon, L., Hoffmann, A. R. F., Botz, A., and Khemtemourian, L. (2016) Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus, *Journal of Diabetes Research* 2016, 1-13.

[53] Jaikaran, E. T. A. S., Higham, C. E., Serpell, L. C., Zurdo, J., Gross, M., Clark, A., and Fraser, P. E. (2001) Identification of a novel human islet amyloid polypeptide β-sheet domain and factors influencing fibrillogenesis, *Journal of Molecular Biology* 308, 515-525.

[54] Sun, Y., Wang, B., Ge, X., and Ding, F. (2017) Distinct oligomerization and fibrillization dynamics of amyloid core sequences of amyloid-beta and islet amyloid polypeptide, *Phys. Chem. Chem. Phys.* 19, 28414-28423.

[55] Zanuy, D., Ma, B., and Nussinov, R. (2003) Short peptide amyloid organization: Stabilities and conformations of the islet amyloid peptide NFGAIL, *Biophysical Journal* 84, 1884-1894.

[56] Balbach, J. J., Ishii, Y., Antzutkin, O. N., Leapman, R. D., Rizzo, N. W., Dyda, F., Reed, J., and Tycko, R. (2000) Amyloid fibril formation by Aβ16-22, a seven-residue fragment of the Alzheimer’s β-amyloid peptide, and structural characterization by solid state NMR, *Biochemistry* 39, 13748-13759.
[57] Klimov, D. K., and Thirumalai, D. (2003) Dissecting the assembly of Aβ16-22 amyloid peptides into antiparallel β sheets, *Structure* 11, 295-307.

[58] Young, L. M., Mahood, R. A., Saunders, J. C., Tu, L. H., Raleigh, D. P., Radford, S. E., and Ashcroft, A. E. (2015) Insights into the consequences of co-polymerisation in the early stages of IAPP and Aβ peptide assembly from mass spectrometry, *Analyst* 140, 6990-6999.

[59] Andreetto, E., Yan, L.-M., Caporale, A., and Kapurniotu, A. (2011) Dissecting the Role of Single Regions of an IAPP Mimic and IAPP in Inhibition of Aβ40 Amyloid Formation and Cytotoxicity, *ChemBioChem* 12, 1313-1322.

[60] Oostenbrink, C., Villa, A., Mark, A. E., and Van Gunsteren, W. F. (2004) A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force-field parameter sets 53A5 and 53A6, *Journal of computational chemistry* 25, 1656-1676.

[61] Crescenzi, O., Tomaselli, S., Guerrini, R., Salvadori, S., D'Ursi, A. M., Temussi, P. A., and Picone, D. (2002) Solution structure of the Alzheimer amyloid β-peptide (1-42) in an apolar microenvironment, *European Journal of Biochemistry* 269, 5642-5648.

[62] Nanga, R. P. R., Breder, J. R., Vivekanandan, S., and Ramamoorthy, A. (2011) Structure and membrane orientation of IAPP in its natively amidated form at physiological pH in a membrane environment, *Biochimica et Biophysica Acta - Biomembranes* 1808, 2337-2342.

[63] Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., and Hermans, J. (1981) Interaction Models for Water in Relation to Protein Hydration, pp 331-342, Springer, Dordrecht.

[64] Berendsen, H. J. C., Postma, J. P. M., Van Gunsteren, W. F., Dinola, A., and Haak, J. R. (1984) Molecular dynamics with coupling to an external bath, *The Journal of Chemical Physics* 81, 3684-3690.

[65] Bussi, G., Donadio, D., and Parrinello, M. (2007) Canonical sampling through velocity rescaling, *Journal of Chemical Physics* 126, 014101-014101.

[66] Nosé, S., and Klein, M. L. (1983) Constant pressure molecular dynamics for molecular systems, *Molecular Physics* 50, 1055-1076.

[67] Parrinello, M., and Rahman, A. (1981) Polymorphic transitions in single crystals: A new molecular dynamics method, *Journal of Applied Physics* 52, 7182-7190.

[68] Hess, B. (2008) P-LINCS: A parallel linear constraint solver for molecular simulation, *Journal of Chemical Theory and Computation* 4, 116-122.

[69] Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems, *The Journal of Chemical Physics* 98, 10089-10092.

[70] Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., and Pedersen, L. G. (1995) A smooth particle mesh Ewald method, *The Journal of Chemical Physics* 103, 8577-8593.

[71] Daura, X., Gademann, K., Jaun, B., Seebach, D., Gunsteren, W. F. v., and Mark, A. E. (1999) Peptide Folding: When Simulation Meets Experiment, *Angewandte Chemie International Edition* 38, 236-240.

[72] Brown, A. M., and Bevan, D. R. (2016) Molecular Dynamics Simulations of Amyloid β-Peptide (1-42): Tetramer Formation and Membrane Interactions, *Biophysical journal* 111, 937-949.

[73] The PyMOL Molecular Graphics System, Version 2.2.0 ed., Schrodinger, LLC.

[74] Kabsch, W., and Sander, C. (1983) Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features, *Biopolymers* 22, 2577-2637.

[75] Abel, S., Sterpone, F., Bandyopadhyay, S., and Marchi, M. (2004) Molecular modeling and simulations of AOT-water reverse micelles in isooctane: Structural and dynamic properties, *Journal of Physical Chemistry B* 108, 19458-19466.
[76] Martinez, A. V., Dominguez, L., Malolepsza, E., Moser, A., Ziegler, Z., and Straub, J. E. (2013) Probing the structure and dynamics of confined water in AOT reverse micelles, *Journal of Physical Chemistry B* 117, 7345-7351.

[77] Ruggeri, F. S., Longo, G., Faggiano, S., Lipiec, E., Pastore, A., and Dietler, G. (2015) Infrared nanospectroscopy characterization of oligomeric and fibrillar aggregates during amyloid formation, *Nature Communications* 6, 1-9.

[78] Yang, D. S., Yip, C. M., Huang, T. H. J., Chakrabarty, A., and Fraser, P. E. (1999) Manipulating the amyloid-β aggregation pathway with chemical chaperones, *Journal of Biological Chemistry* 274, 32970-32974.

[79] Strodel, B. (2021) Amyloid aggregation simulations: challenges, advances and perspectives, *Curr Opin Struct Biol* 67, 145-152.

[80] Sun, Y., Kakinen, A., Wan, X., Moriarty, N., Hunt, C. P. J., Li, Y., Andrikopoulos, N., Nandakumar, A., Davis, T. P., Parish, C. L., Song, Y., Ke, P. C., and Ding, F. (2021) Spontaneous formation of β-sheet nano-barrels during the early aggregation of Alzheimer's amyloid beta, *Nano Today* 38, 101125.

[81] Kabsch, W., and Sander, C. (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features, *Biopolymers* 22, 2577-2637.

[82] Cerf, E., Sarroukh, R., Tamamizu-Kato, S., Breydo, L., Derclayes, S., Dufrênes, Y. F., Narayanaswami, V., Goormaghtigh, E., Ruysschaert, J. M., and Raussens, V. (2009) Antiparallel β-sheet: A signature structure of the oligomeric amyloid β-peptide, *Biochemical Journal* 421, 415-423.

[83] Soriaga, A. B., Sangwan, S., Macdonald, R., Sawaya, M. R., and Eisenberg, D. (2016) Crystal Structures of IAPP Amyloidogenic Segments Reveal a Novel Packing Motif of Out-of-Register Beta Sheets, *J Phys Chem B* 120, 5810-5816.

[84] Favrin, G., Irbäck, A., and Mohanty, S. (2004) Oligomerization of amyloid Aβ16-22 peptides using hydrogen bonds and hydrophobicity forces, *Biophysical Journal* 87, 3657-3664.

[85] Ge, X., Sun, Y., and Ding, F. (2018) Structures and dynamics of β-barrel oligomer intermediates of amyloid-beta16-22 aggregation, *Biochimica et Biophysica Acta - Biomembranes* 1860, 1687-1697.

[86] Serra-Batiste, M., Ninot-Pedrosa, M., Bayoumi, M., Gairí, M., Maglia, G., and Carulla, N. (2016) Aβ42 assembles into specific β-barrel pore-forming oligomers in membrane-mimicking environments, *Proceedings of the National Academy of Sciences of the United States of America* 113, 10866-10871.

[87] Nguyen, P. H., Campanera, J. M., Ngo, S. T., Loquet, A., and Derreumaux, P. (2019) Tetrameric Aβ40 and Aβ42 β-Barrel Structures by Extensive Atomistic Simulations. I. in a Bilayer Mimicking a Neuronal Membrane, *Journal of Physical Chemistry B* 123, 3643-3648.

[88] Sun, Y., Ge, X., Xing, Y., Wang, B., and Ding, F. (2018) β-barrel Oligomers as Common Intermediates of Peptides Self-Assembling into Cross-β Aggregates, *Scientific Reports* 8, 10353.

[89] Pan, J., Han, J., Borchers, C. H., and Konermann, L. (2012) Structure and Dynamics of Small Soluble Aβ(1–40) Oligomers Studied by Top-Down Hydrogen Exchange Mass Spectrometry, *Biochemistry* 51, 3694-3703.

[90] Laganowsky, A., Liu, C., Sawaya, M. R., Whitelegge, J. P., Park, J., Zhao, M., Pensalfini, A., Soriaga, A. B., Landau, M., Teng, P. K., Cascio, D., Glabe, C., and Eisenberg, D. (2012) Atomic View of a Toxic Amyloid Small Oligomer, *Science* 335, 1228.

[91] Liu, C., Zhao, M., Jiang, L., Cheng, P.-N., Park, J., Sawaya, M. R., Pensalfini, A., Gou, D., Berk, A. J., Glabe, C. G., Nowick, J., and Eisenberg, D. (2012) Out-of-register β-sheets suggest a pathway to toxic amyloid aggregates, *Proceedings of the National Academy of Sciences of the United States of America* 109, 20913-20918.
[92] Jang, H., Arce, F. T., Ramachandran, S., Capone, R., Lal, R., and Nussinov, R. (2010) β-Barrel topology of Alzheimer's β-amyloid ion channels, *J Mol Biol* 404, 917-934.